The following is a summary of “BCMA CAR-T therapy as salvage therapy in patients with plasmablastic myeloma,” published in ...

CAR-T therapy for myeloma faces challenges in early-line use due to accessibility, eligibility criteria and long wait times, ...

Bristol-Myers Squibb’s anti-BCMA CAR-T therapy ide-cel is in pole ... in heavily pre-treated multiple myeloma patients. Updated results from the phase 1b/2 study show that impressive response ...

A clinical team has spearheaded the use of CAR-T cell therapy for blood cancers. The researchers recently treated the first ...

Several studies have been conducted, but questions remain about where such therapies will fit into multiple myeloma treatment ...

This CAR helps the T cells recognize and destroy cells expressing BCMA, which is primarily found in malignant multiple myeloma B-lineage cells, late-stage B cells, and plasma cells. The CARVYKTI ...

Both of them, like Abecma, fight multiple myeloma by targeting B cell maturation antigen (BCMA). According to BMS, Abecma generated a total of $406 million in worldwide product revenue ...

When Mateo Mejia Saldarriaga, MD, first started seeing multiple myeloma (MM) patients as a medical ... target B-cell maturation antigen (BCMA) and have high response rates in patients with late ...

BCMA and GPRC5D loss in patients with multiple myeloma may lead to resistance to continuous treatment with anti–BCMA and anti–GPRC5D agents. A recent study suggests that a patient’s immune ...